Age-Related Sex Differences in Clinical Presentation, Management, and Outcomes in ST-Segment–Elevation Myocardial Infarction: Pooled Analysis of 15 532 Patients From 7 Arabian Gulf Registries

Abdulla Shehab, MBChB, PhD; Akshaya Srikanth Bhagavathula, PharmD, PhD student; Khalid F. Alhabib, MBBS; Anhar Ullah, MSc; Jassim Al Suwaidi, MBChB; Wael Almahmeed, BM; Hussam AlFaleh, BM; Mohammad Zubaid, MBChB

Background—No studies from the Arabian Gulf region have taken age into account when examining sex differences in ST-segment–elevation myocardial infarction (STEMI) presentation and outcomes. We examined the relationship between sex differences and presenting characteristics, revascularization procedures, and in-hospital mortality after accounting for age in patients hospitalized with STEMI in the Arabian Gulf region from 2005 to 2017.

Methods and Results—This study was a pooled analysis of 31 620 patients with a diagnosis of acute coronary syndrome enrolled in 7 Arabian Gulf registries. Of these, 15 532 patients aged ≥18 years were hospitalized with a primary diagnosis of STEMI. A multiple variable regression model was used to assess sex differences in revascularization, in-hospital mortality, and 1-year mortality. Odds ratios and 95% CIs were calculated. Women were, on average, 8.5 years older than men (mean age: 61.7 versus 53.2 years; absolute standard mean difference: 68.9%). The age-stratified analysis showed that younger women (aged <65 years) with STEMI were more likely to seek acute medical care and were less likely to receive thrombolytic therapies or primary percutaneous coronary intervention and guideline-recommended pharmacotherapy than men. Women had higher crude in-hospital mortality than men, driven mainly by younger age (46–55 years, odds ratio: 2.60 [95% CI, 1.80–3.7]; P<0.001; 56–65 years, odds ratio: 2.32 [95% CI, 1.75–3.08]; P<0.001; and 66–75 years, odds ratio: 1.79 [95% CI, 1.33–2.41]; P<0.001). Younger women had higher adjusted in-hospital and 1-year mortality rates than younger men (P<0.001).

Conclusions—Younger women (aged ≤65 years) with STEMI were less likely to receive guideline-recommended pharmacotherapy and revascularization than younger men during hospitalization and had higher in-hospital and 1-year mortality rates. (J Am Heart Assoc. 2020;9:e013880. DOI: 10.1161/JAHA.119.013880.)

Key Words: acute coronary syndrome • hospitalization • Middle East • mortality • myocardial infarction • sex • STEMI

Cardiovascular disease is the leading cause of morbidity and mortality, and women have worse outcomes after acute coronary syndrome (ACS) than men.1,2 Over the past decade, emerging findings have revealed sex-specific differences in ACS regarding clinical presentation, pathophysiology, diagnosis, and management in women.3–12 These major gaps are further compounded by the underrepresentation of women in cardiovascular clinical trials.10 Studies have shown that women with ST-segment–elevation myocardial infarction (STEMI) have worse short- and long-term outcomes than men.12–17 Some prognostic factors include older age at presentation, more comorbidities, and the presence of atypical symptoms, which might explain the delay in seeking treatment of women presenting with STEMI.3,7,12,15–20 These atypical symptoms can be further associated with the delay in diagnosis and management and thus worse clinical outcomes.
Clinical Perspective

What Is New?

- Women receive guideline-recommended pharmacotherapies at hospital discharge less frequently than men.
- In particular, younger women (aged \( \leq 65 \) years) with ST-segment–elevation myocardial infarction (STEMI) were less likely to receive guideline-recommended pharmacotherapy and revascularization than younger men during hospitalization and had higher in-hospital and 1-year mortality rates.
- These findings suggest both sex- and age-specific influences on STEMI and provide a possible explanation for sex differences in STEMI outcomes.

What Are the Clinical Implications?

- Our pooled analysis of the 7 major acute coronary syndrome registries in the Arabian Gulf region from 2005 to 2017 suggests that young women with STEMI are a unique high-risk group that presents a diagnostic challenge for clinicians.
- Although women and men with STEMI derive similar treatment effects, beta-blockers and statins at discharge are still underprescribed for women.

Previous registries from the Arabian Gulf countries (Kuwait, Qatar, Bahrain, United Arab Emirates, Oman, Yemen, and Saudi Arabia) have included STEMI and non–ST-segment–elevation myocardial infarction (NSTEMI) patients and have shown that women presenting with ACS have higher rates of in-hospital mortality than men.\(^3\),\(^12\),\(^21\)–\(^23\) Examining potential age–sex disparities in STEMI outcomes in the Gulf region is important because the currently published data are limited by small sample sizes among the different age subgroups of women versus men. Therefore, we sought to examine the relationship between sex differences and presenting characteristics, revascularization procedures, and in-hospital mortality among the different age groups in patients hospitalized with STEMI in a pooled analysis of the 7 major ACS registries in the Arabian Gulf region from 2005 to 2017.

Methods

The registry data will not be made available, but STEMI-specific data will be made available on request from the corresponding author.

Data Source

All 7 ACS registries had a prospective consecutive study design. The study cohort consisted of records of patients hospitalized with ACS in 7 Arabian Gulf countries from 2005 to 2017.\(^3\),\(^2\),\(^1\),\(^2\),\(^24\)–\(^27\) The overview of the individual studies is summarized in Table 1. Two of 7 studies were national registries (Saudi Arabia and Kuwait) and used standard definitions according to published American College of Cardiology/European Society of Cardiology (ACC/ESC) guidelines.\(^28\)–\(^35\) The databases were merged using a standard uniform coding strategy after an extensive review of the original coding system of each registry. Data related to patient characteristics; clinical presentation; management during hospital stay, including medications, reperfusion therapy and procedures, outcomes, and discharge medications; in-hospital mortality; and 1-year mortality were included in the study.

Each registry was approved by the ethics committee at its respective institution and were developed according to the Declaration of Helsinki. Because the patient information was collected anonymously, institutional review boards waived the need for individual informed consent.

Study Population

From 2005 to 2017, a total of 31 620 patients with a diagnosis of ACS were enrolled in 7 Arabian Gulf registries. Of these, 15 532 patients aged \( \geq 18 \) years were hospitalized with a primary diagnosis of STEMI.

Study Variables

For the analysis, we collected the patient characteristics, baseline risk profile, medical history at presentation, initial assessment and management, in-hospital investigation and clinical management, all-cause in-hospital mortality, and 1-year mortality. Age was stratified into subgroups as follows: 18 to 45, 46 to 55, 56 to 65, 66 to 75, and \( \geq 75 \) years.\(^18\),\(^36\)

Statistical Analysis

Sex was compared for clinical characteristics; clinical presentation; management during hospital stay, including medications, reperfusion therapy and procedures, and in-hospital and discharge medications used; all-cause in-hospital mortality; and 1-year mortality. Categorical data were summarized with absolute numbers and percentages. Numeric data were summarized with mean±SD. Baseline characteristics of men and women were compared using the Pearson chi-square test or Fisher exact test for categorical variables. The Student \( t \) test or Mann–Whitney \( U \) test was used for continuous variables. In addition, we computed absolute standardized differences (ASDs) to compare the baseline characteristics with sex. The ASD is calculated as the difference in means or proportions divided by a pooled estimate of the SD and is reported in percentages. ASD is not as sensitive as traditional
significance testing to sample size and is useful for identifying clinically meaningful differences (ASD >10%).37

Logistic multiple variable regression models were used to assess sex differences in revascularization, in-hospital mortality, and 1-year mortality. Crude and adjusted odds ratios (ORs) with 95% CIs were calculated with men as the reference group. Adjustments were performed for sociodemographics (age, ethnicity), the presence of cardiovascular risk factors (diabetes mellitus, obesity [body mass index >25], hypertension, hypercholesterolemia, and smoking), hospital-level characteristics (echocardiogram and Killip class), revascularization therapy (a history of percutaneous coronary intervention [PCI] or coronary artery bypass grafting), a history of myocardial infarction or stroke, and the time from symptom onset to arrival at the emergency department (ED). Two-tailed tests were used, and \( P < 0.001 \) was considered statistically significant. All analyses were performed using SAS/STAT software v9.2 (SAS Institute).

### Results

Of the 15,532 patients aged \( \geq 18 \) years hospitalized with STEMI in the 7 Gulf registries from 2005 to 2017, 2033 (29.7%) were women. Women were, on average, 8.5 years older than men (mean age: 61.7 versus 53.2 years; ASD: 68.9%). The presence of diabetes mellitus, hypertension, hypercholesterolemia, prior stroke, heart failure, and myocardial infarction was significantly higher in women (ASD >10% for all). However, complaints of chest pain (87% versus 94%), Killip class I (73.8% versus 83.3%), PCI (9.1% versus 11.5%), time from symptom onset to hospital arrival (<3 hours: 41.3% versus 53.3%), ED-to-needle time (<30 minutes: 21.1% versus 29.2%), and ED-to-balloon time (<90 minutes: 46.3% versus 62.5%) were lower in women than in men (Table 2). Age-stratified analysis showed more cardiovascular risk factors for STEMI in women aged 56 to 65 years than men: higher body mass index (\( \geq 25 \); 72.1% versus 64.5%), hypercholesterolemia (40.6% versus 30.4%),

### Table 1. Overview of Observational ACS Registries in the Arabian Gulf Countries From 2005 to 2017 (31,620 ACS Patients)

| Registries     | ACS patients, n (%) | No. of hospitals | Published (reference) | PCI hospitals, % | Countries                      | Baseline recruitment period (mo) | Inclusion criteria | STEMI patients (N=15,532), n (%) | In-hospital outcomes | 1-mo follow-up, n (%) | 1-y follow-up, n (%) |
|----------------|---------------------|------------------|-----------------------|-----------------|--------------------------------|----------------------------------|---------------------|------------------------|----------------------|----------------------|---------------------|
| SPACE          | 5055 (15.9)         | 17               | Yes24                 | 71              | KSA                            | 2005–2007 (24)                   | \( \geq 18 \) y, STEMI, NSTEMI, UA | 2097 (13.5)           | Yes | No                  | No                  |
| Gulf RACE      | 8176 (25.8)         | 64               | Yes21                 | 20              | Kuwait, Qatar, Bahrain, UAE, Oman, Yemen | 2006–2007 (6)                   | \( \geq 18 \) y, STEMI, NSTEMI, UA | 3200 (20.6)           | Yes | No                  | No                  |
| Gulf RACE-2    | 7930 (25)           | 65               | Yes3                  | 43              | KSA, Qatar, Bahrain, UAE, Oman, Yemen | 2008–2009 (9)                   | \( \geq 18 \) y, STEMI, NSTEMI, UA | 3613 (23.2)           | Yes | 3033 (83.9)         | 2780 (76.9)         |
| Gulf COAST     | 4061 (12.8)         | 29               | Yes25                 | 31              | Kuwait, Bahrain, UAE, Oman, Yemen | 2012–2013 (12)                  | \( \geq 18 \) y, STEMI, NSTEMI, UA | 1015 (6.5)            | Yes | 981 (96.6)          | 925 (91.1)          |
| Gulf RACE-3    | 2928 (9.2)          | 36               | Yes26                 | 61              | KSA, Kuwait, Qatar, Bahrain, UAE, Oman | 2014–2015 (12)*                 | \( \geq 18 \) y, STEMI, who received reperfusion | 2928 (18.8)           | Yes | 1208 (100)         | No                  |
| Kuwait REPERFUSE | 1237 (3.9)         | 7                | No                    | 43              | Kuwait                          | 2014–2015 (12)*                  | \( \geq 18 \) y, STEMI, NSTEMI | 1208 (7.7)            | Yes | 1176 (97.3)         | No                  |
| STARS          | 2233 (7)            | 50               | Yes27                 | 40              | KSA                            | 2015–2017 (21)**                 | \( \geq 18 \) y, STEMI, NSTEMI | 1471 (9.4)            | Yes | 888 (60.3)          | No                  |

ACS indicates acute coronary syndrome; Gulf COAST, Gulf Locals With Acute Coronary Syndrome Events Registry; Gulf RACE, Gulf Registry of Acute Coronary Events; KSA, Kingdom of Saudi Arabia; Kuwait REPERFUSE, Reperfusion in ST-Segment–Elevation Myocardial Infarction; NSTEMI, non–ST-segment–elevation myocardial infarction; PCI, percutaneous coronary intervention; SPACE, Saudi Project for Assessment of Coronary Events; STARS, Saudi Acute Myocardial Infarction Registry; STEMI, ST-segment–elevation myocardial infarction; UA, unstable angina; UAE, United Arab Emirates.

*January 2014 to January 2015.
†November 2014 to November 2015.
‡Ongoing follow-up.
Table 2. Baseline Demographics, Comorbidities, and Other Patient Characteristics in Women Versus Men With STEMI

|                                | Total (N=15,532) | Men (n=13,499) | Women (n=2,033) | P Value | ASD, % |
|--------------------------------|------------------|----------------|-----------------|---------|--------|
| Age, y, mean±SD                | 54.38±12.38      | 53.27±11.96    | 61.73±12.60     | <0.001  | 68.9   |
| Age group, y                   |                  |                |                 |         |        |
| 18–45                          | 3862 (24.8)      | 3649 (27)      | 213 (10.4)      | <0.001  | 67.24  |
| 46–55                          | 5115 (32.9)      | 4669 (34.6)    | 446 (21.9)      |         |        |
| 56–65                          | 3790 (24.4)      | 3156 (23.3)    | 634 (31.2)      |         |        |
| 66–75                          | 1942 (12.5)      | 1455 (10.7)    | 487 (23.9)      |         |        |
| ≥75                            | 823 (5.3)        | 570 (4.2)      | 253 (12.4)      |         |        |
| Body mass index*               |                  |                |                 |         |        |
| ≤24.99                         | 4988 (34.5)      | 4411 (35.1)    | 577 (30.7)      | <0.001  | 9.36   |
| ≥25                            | 9451 (64.5)      | 8150 (64.8)    | 1301 (69.2)     | <0.001  |        |
| Ethnicity                      |                  |                |                 |         |        |
| Arab                           | 9031 (58.1)      | 7263 (53.8)    | 1768 (86.9)     | <0.001  | 79.67  |
| Non-Arab                       | 6501 (41.86)     | 6236 (46.20)   | 265 (13.03)     |         |        |
| Type of STEMI*                 |                  |                |                 |         |        |
| Anterior                       | 7455 (53.9)      | 6581 (54.4)    | 874 (50.5)      | <0.001  | 9.33   |
| Inferior                       | 5538 (40)        | 4811 (39.8)    | 727 (42)        |         |        |
| Other                          | 821 (5.9)        | 692 (5.7)      | 129 (7.4)       |         |        |
| History of MI angina           | 3051 (19.6)      | 2567 (19)      | 484 (23.8)      | <0.001  | 11.7   |
| History of PCI                 | 892 (5.7)        | 778 (5.7)      | 114 (5.6)       | 0.807   | 0.58   |
| History of CABG                | 1379 (8.9)       | 1268 (9.4)     | 111 (5.4)       | <0.001  | 15.07  |
| History of heart failure       | 199 (2.2)        | 150 (1.9)      | 49 (4.1)        | <0.001  | 13.16  |
| History of stroke              | 523 (3.3)        | 378 (2.8)      | 145 (7.1)       | <0.001  | 20.15  |
| History of chronic renal failure| 211 (1.5)        | 154 (1.3)      | 57 (3.3)        | <0.001  | 13.54  |
| Diabetes mellitus              | 6108 (39.5)      | 4966 (36.9)    | 1142 (56.5)     | <0.001  | 40.07  |
| Hypertension                   | 5991 (38.7)      | 4793 (35.6)    | 1198 (59.2)     | <0.001  | 48.71  |
| Hypercholesterolemia           | 3933 (26.6)      | 3263 (25.4)    | 670 (34.4)      | <0.001  | 19.83  |
| Current or ex-smoking          | 8930 (57.5)      | 8432 (62.4)    | 498 (24.5)      | <0.001  | 82.91  |
| Chief complaint                |                  |                |                 |         |        |
| Chest pain                     | 13 855 (93.1)    | 12 174 (94)    | 1681 (87)       | <0.001  | 24.22  |
| Cardiac arrest                 | 116 (0.7)        | 92 (0.7)       | 24 (1.2)        |         |        |
| Other                          | 903 (6)          | 677 (5.2)      | 226 (11.7)      |         |        |
| Killip class                   |                  |                |                 |         |        |
| I                              | 12 466 (82)      | 11 004 (83.3)  | 1462 (73.8)     | <0.001  | 23.52  |
| II/III                         | 2267 (14.9)      | 1848 (14)      | 419 (21.1)      |         |        |
| IV                             | 460 (3)          | 360 (2.7)      | 100 (5)         |         |        |
| Echo options                   |                  |                |                 |         |        |
| Normal LV function             | 3550 (25.5)      | 3131 (25.8)    | 419 (23.2)      | <0.001  | 11.48  |
| Mild LV dysfunction            | 5852 (42.1)      | 5133 (42.4)    | 719 (39.8)      |         |        |
| Moderate LV dysfunction        | 2996 (21.5)      | 2545 (21)      | 451 (24.9)      |         |        |
| Severe LV dysfunction          | 1505 (10.8)      | 1287 (10.6)    | 218 (12)        |         |        |
| Elective PCI                   | 1588 (10.9)      | 1419 (11.1)    | 169 (8.1)       | 0.010   | 6.59   |

Continued
Table 2. Continued

|                          | Total (N=15,532) | Men (n=13,499) | Women (n=2,033) | P Value | ASD, % |
|--------------------------|------------------|---------------|----------------|---------|--------|
| CABG                     | 382 (2.6)        | 333 (2.6)     | 49 (2.7)       | 0.923   | 0.24   |
| Ambulance                | 3444 (23.3)      | 2992 (23.2)   | 452 (23.8)     | 0.565   | 2.11   |

Symptom-to-hospital-arrival time

- **<3 h**: 6390 (51.9) vs. 5789 (53.3), P<0.001 (28.76 SD)
- **3–12 h**: 4553 (37) vs. 3945 (36.3), P<0.05 (19.06 SD)
- **>12–24 h**: 1361 (11) vs. 1114 (10.2), P<0.05 (19.06 SD)

Symptom-to-ED time, min, mean±SD

- **<10 min**: 170.0±257 vs. 164.0±248.5, P<0.001 (29.2 SD)
- **10–30 min**: 9.00±10 vs. 9.00±10, P<0.001 (16.99 SD)
- **>30–60 min**: 6010 (51) vs. 5407 (52.1), P<0.001 (19.26 SD)
- **>60 min**: 40.00±44 vs. 40.00±43, P<0.001 (21.86 SD)

In-Hospital Outcomes

Women had higher crude in-hospital mortality than men. The higher in-hospital mortality in women was driven by younger age (46–55 years, OR: 2.61 [95% CI, 1.80–3.7]; P<0.001; 56–65 years, OR: 2.32 [95% CI, 1.75–3.08]; P=0.001). This association between female sex and in-hospital mortality was significant after adjusting for age, baseline characteristics, and comorbidities (46–55 years, adjusted OR: 2.28 [95% CI, 1.44–3.61]; P<0.001; 56–65 years, adjusted OR: 1.89 [95% CI, 1.34–2.64]; P<0.001; Table 5). Additional stepwise adjustment for the use of revascularization showed a significant association of female sex with in-hospital mortality in the age subgroups 46 to 55 years (P=0.005) and 56 to 65 years (P=0.003).

One-Year Mortality

Younger women (aged ≤65 years) were more than twice at risk of 1-year mortality than younger men (P<0.001). For older patients (aged >65 years), women had a 59% higher risk of 1-year mortality than men. After adjusting for demographics, baseline characteristics, and comorbidity, female sex still had higher 1-year mortality than male sex (aged ≤65 years, OR: 1.89 [95% CI, 1.38–2.58]; aged >65 years, OR: 1.58 [95% CI, 1.12–2.23]). This excess mortality was still persistent in young women (aged ≤65 years) after adjusting for revascularization and the time from symptom onset to arrival at the ED (Table 6).

Discussion

This pooled analysis of 7 ACS registries represents the first study to assess the relationship of age-stratified sex differences in the clinical presentation, management, and in-hospital...
**Table 3.** Age-Stratified Prevalence of Comorbidities in Women Versus Men With STEMI

| Age Category | Men, n (%) | Women, n (%) | P Value | ASD, % | Men, n (%) | Women, n (%) | P Value | ASD, % | Men, n (%) | Women, n (%) | P Value | ASD, % |
|--------------|------------|--------------|---------|--------|------------|--------------|---------|--------|------------|--------------|---------|--------|
| Current/ex-smoking | 2396 (71.1) | 50 (23.4) | <0.001 | 108.66 | 3082 (66) | 121 (27.1) | <0.001 | 1789 (66.6) | 152 (23.9) | <0.001 | 719 (49.4) | 113 (23.2) | <0.001 |
| Body mass index | | | | | | | | | | | | | |
| ≤24.99 | 1215 (35.6) | 56 (27.8) | 0.024 | 16.84 | 1399 (32.1) | 130 (28.7) | 0.154 | 7.4 | 1041 (35.4) | 160 (27.8) | <0.001 | 512 (37.9) | 157 (34.4) | 0.181 |
| ≥25 | 2191 (64.3) | 145 (72.1) | 0.001 | 37.92 | 2986 (67.9) | 298 (71.3) | 0.001 | 37.92 | 1884 (64.5) | 415 (72.1) | <0.001 | 838 (62) | 299 (65.5) | <0.001 |
| Hypercholesterolemia | 647 (18.8) | 42 (20.6) | 0.528 | 4.48 | 1138 (25.6) | 142 (33.5) | <0.001 | 21.44 | 917 (30.4) | 246 (40.8) | <0.001 | 427 (30.8) | 169 (35.7) | 0.041 |
| MI/angina | 449 (12.3) | 38 (17.8) | 0.018 | 15.52 | 846 (18.1) | 85 (19) | 0.023 | 4.21 | 688 (21.8) | 162 (25.3) | 0.040 | 419 (28.8) | 133 (27.3) | 0.539 |
| PCI | 139 (3.8) | 4 (1.9) | 0.147 | 11.65 | 266 (5.7) | 14 (3.1) | 0.024 | 12.46 | 223 (7.1) | 42 (6.6) | 0.702 | 118 (8.1) | 37 (7.6) | 0.749 |
| CABG | 265 (7.3) | 7 (3.3) | 0.027 | 17.9 | 478 (10.2) | 27 (6.1) | 0.005 | 15.38 | 385 (12.2) | 40 (6.3) | <0.001 | 106 (7.3) | 25 (5.1) | 0.108 |
| Diabetes mellitus | 836 (23.5) | 85 (39.9) | <0.001 | 35.64 | 1807 (38.8) | 264 (39.6) | <0.001 | 42.41 | 1433 (45.6) | 388 (61.8) | <0.001 | 655 (45.2) | 284 (58.8) | <0.001 |
| Hypertension | 765 (21) | 88 (42.1) | <0.001 | 46.52 | 1664 (35.7) | 241 (54.2) | <0.001 | 42.41 | 1385 (44) | 389 (61.8) | <0.001 | 714 (49.3) | 312 (64.4) | <0.001 |
| Heart failure | 11 (0.3) | 0 | 0.432 | 10.18 | 28 (1) | 8 (3.1) | 0.004 | 14.56 | 47 (2.8) | 18 (4.9) | 0.017 | 12.32 | 45 (5.3) | 19 (6.44) |
| Stroke | 23 (0.6) | 7 (3.3) | <0.001 | 19.23 | 70 (1.5) | 21 (4.7) | <0.001 | 18.68 | 119 (3.7) | 44 (6.9) | <0.001 | 14.14 | 103 (2.1) | 41 (6.5) |
| Chronic renal failure | 14 (0.4) | 1 | <0.001 | 0.57 | 25 (0.6) | 7 (1.9) | 0.005 | 11.62 | 48 (1.7) | 20 (3.7) | <0.001 | 12.23 | 39 (3.2) | 18 (4.3) |

P values (<0.001) are for men and women within age category. ASD indicates absolute standardized difference; CABG, coronary artery bypass grafting; MI, myocardial infarction; PCI, percutaneous coronary intervention; STEMI, ST-segment-elevation myocardial infarction.
Table 4. Age-Stratified Prevalence of In-Hospital Management and Medications Used in Women Versus Men for STEMI

| Age Group       | Men, n (%) | Women, n (%) | P Value | ASD, % | Men, n (%) | Women, n (%) | P Value | ASD, % | Men, n (%) | Women, n (%) | P Value | ASD, % |
|-----------------|------------|--------------|---------|--------|------------|--------------|---------|--------|------------|--------------|---------|--------|
| 18–45 y         | Thrombolytic therapy given | 1959 (56.6) | 99 (49.5) | 0.048 | 14.3 | 2637 (55.1) | 200 (47.6) | 0.003 | 15.11 | 1415 (47) | 251 (43.9) | 0.078 | 7.99 |
| 46–55 y         | Primary PCI done | 828 (23.9) | 32 (16) | 0.010 | 19.94 | 1047 (23.7) | 75 (17.8) | 0.007 | 14.42 | 740 (28.4) | 99 (16.9) | <0.001 | 18.84 |
| 56–65 y         | No reperfusion | 673 (19.4) | 69 (34.5) | <0.001 | 34.41 | 186 (21.1) | 145 (34.5) | <0.001 | 30.1 | 854 (28.3) | 233 (39.9) | <0.001 | 24.61 |
| 66–75 y         | Late presentation | 411 (62.3) | 55 (80.8) | 0.006 | 51.8 | 609 (66.7) | 105 (74.4) | 0.032 | 28.73 | 570 (68.5) | 159 (71.3) | 0.244 | 15.55 |
| ≥75 y           | Missed | 36 (5.4) | 1 (1.4) | <0.001 | 42 (4.6) | 6 (4.2) | 47 (5.6) | 12 (6.3) | 23 (4.6) | 7 (3.8) | 27 (2.9) | 7 (2.7) | 2 (1.9) |
|                 | Contraindication | 34 (5.1) | 5 (7.3) | <0.001 | 38 (6.3) | 13 (9.2) | 54 (6.9) | 20 (8.9) | 44 (6.6) | 19 (10.3) | <0.001 | 33 (13.1) | 15 (14.4) |
|                 | Other | 178 (27) | 7 (10.3) | <0.001 | 204 (22.3) | 17 (12) | 161 (19.3) | 32 (14.3) | 92 (18.3) | 38 (20.6) | <0.001 | 34 (1.4) | 22 (21.1) |
|                 | Medication 24 h | 3062 (83.9) | 209 (98.5) | 0.763 | 2.04 | 4625 (99.2) | 438 (98.8) | 0.422 | 3.67 | 3088 (84.4) | 622 (98.5) | 0.500 | 2.83 |
|                 | Other antiplatelet | 3062 (83.9) | 168 (78.8) | 0.053 | 12.98 | 4007 (85.9) | 369 (82.7) | 0.077 | 8.49 | 2629 (63.3) | 487 (76.8) | <0.001 | 16.29 |
|                 | Beta-blockers | 2739 (75.4) | 155 (73.1) | 0.446 | 5.31 | 3471 (74.9) | 323 (72.9) | 0.460 | 3.85 | 2307 (70.1) | 438 (69.1) | 0.601 | 2.27 |
|                 | ACE/ARB | 2632 (72.4) | 160 (75.4) | 0.328 | 7.03 | 3393 (72.7) | 335 (75.2) | 0.256 | 5.71 | 2279 (73.7) | 457 (72.2) | 0.937 | 0.34 |
|                 | Statins | 3465 (95.3) | 200 (94.3) | 0.488 | 4.69 | 4449 (95.4) | 410 (92.5) | 0.006 | 12.24 | 2969 (84.3) | 596 (89.4) | 0.738 | 1.44 |
|                 | Aldosterone antagonists/ spironolactone | 77 (5.6) | 7 (16.6) | 0.017 | 30.62 | 112 (8) | 12 (11.8) | 0.173 | 12.96 | 105 (11.4) | 15 (13.3) | 0.988 | 0.13 |
|                 | Heparins, LMWH | 3220 (85.5) | 187 (88.2) | 0.876 | 1.1 | 4138 (88.7) | 404 (90.8) | 0.193 | 6.69 | 2751 (74.7) | 536 (84.5) | 0.033 | 8.2 |
|                 | Glycoprotein IIb/IIIa inhibitors | 712 (19.6) | 29 (13.6) | 0.034 | 15.93 | 912 (19.5) | 60 (13.4) | 0.002 | 16.46 | 625 (19.8) | 81 (22.7) | <0.001 | 19.24 |
|                 | Medication at discharge | 3495 (97.3) | 197 (94.7) | 0.024 | 13.57 | 4449 (96.7) | 401 (93.2) | <0.001 | 16.25 | 2923 (95.2) | 550 (90) | <0.001 | 20.24 |
|                 | Other antiplatelet | 2903 (79.5) | 163 (76.5) | 0.288 | 7.32 | 3768 (80.7) | 339 (76) | 0.017 | 11.42 | 2442 (78.3) | 430 (87.8) | <0.001 | 21.54 |
|                 | ACE/ARB | 3151 (87.3) | 163 (77.6) | <0.001 | 25.84 | 3883 (86.4) | 332 (77) | <0.001 | 24.47 | 2903 (81) | 468 (75.8) | 0.003 | 12.75 |
|                 | Statins | 3328 (92.3) | 197 (88.3) | 0.420 | 5.98 | 4297 (93.2) | 385 (89.3) | 0.003 | 13.79 | 2825 (81.5) | 544 (88.3) | 0.008 | 11.09 |
|                 | Oral anticoagulant warfarin/dabigatran | 64 (2.7) | 2 (1.7) | 0.482 | 7.31 | 96 (3.2) | 17 (6.7) | 0.003 | 16.55 | 68 (3.3) | 15 (4.1) | 0.441 | 4.22 |

P values (<0.001) are for men and women within age category. ACE indicates angiotensin-converting enzyme inhibitor; ARB, angiotensin II receptor blocker; ASD, absolute standardized difference; LMWH, low-molecular-weight heparin; PCI, percutaneous coronary intervention; STEMI, ST-segment-elevation myocardial infarction; UH, unfractionated heparin.
and 1-year mortality rates in patients with STEMI in the Arabian Gulf region. The main findings of our study were as follows. First, women with STEMI had a significantly higher comorbidity burden than men in the same age group. Second, younger women (aged ≤65 years) were more likely to seek acute medical care and less likely to receive guideline-recommended pharmacotherapy than younger men. Third, significantly higher crude and adjusted in-hospital and 1-year mortality rates were observed in younger women than in younger men.

Sex differences in the baseline characteristics, presentation, and mortality of acute myocardial infarction are well known and described repeatedly in our previous work. Limited studies have focused on STEMI. Prior studies mainly reported sex differences in short-term mortality, but after adjusting for age, risk factors, and comorbidities, these differences disappeared. In our study, we observed that younger women (aged ≤65 years) showed 2-fold higher in-hospital mortality than younger men, and younger women showed a significantly increased risk of dying in the hospital and at 1-year follow-up even after adjustment for demographics, baseline characteristics, comorbidities, and revascularization. These findings were in accordance with those of other studies, suggesting that sex differences for in-hospital mortality are driven primarily by the young age groups, with women aged ≤55 years having a significantly increased risk of in-hospital mortality, and those women who survive an acute myocardial infarction having an increased risk of 30-day mortality compared with similarly aged men. The GWTG-CAD (Get With The Guidelines—Coronary Artery Disease) study of a STEMI cohort showed significantly higher in-hospital mortality among women within the first 24 hours of hospitalization. Indeed, some factors such as differences in baseline cardiovascular risk profile and clinical profile, disparities in treatment, and low use of revascularization may be contributing factors in outcomes after STEMI in younger women. Furthermore, poor prognostic factors among older women, including lack of awareness of symptoms, longer delay in hospital presentation, and, consequently, suboptimal total ischemic time to PCI were often reported. From a pathophysiology point of view, women have a higher prevalence of plaque erosion, and men have a higher prevalence of plaque rupture.

Our study data also provided evidence that <50% of women received ECG within 10 minutes, suggesting that sex differences exist in the diagnosis of STEMI. Similar findings were identified in international registries, where longer ED-to-ECG times were observed for women than men. However, some studies discussed that these sex differences might be due to poor recognition of atypical symptoms by emergency physicians, which can contribute to delays in treatment, difficulties in implementation of procedures, transfer to the catheterization laboratory, and referral-hospital acceptance; and technical challenges for women at PCI sites. In our results, there was a sex-specific delay in ED-to-needle time (<30 minutes) caused by delayed ECG examination that affected the ED-to-balloon time (<90 minutes) in women. In particular, a clinically significant lower proportion of younger women (aged <65 years) received

**Table 5.** Age-Stratified Analysis of Use of Revascularization and In-Hospital Mortality in Women Versus Men With STEMI

| Reperfusion | Overall, n (%) | Men, n (%) | Women, n (%) | OR (95% CI) | P Value | Adjusted OR (95% CI) | P Value | Adjusted OR (95% CI) | P Value |
|-------------|----------------|------------|--------------|-------------|---------|----------------------|---------|----------------------|---------|
| **Revascularization** | | | | | | | | | |
| 18–45 y | 2918 (75.5) | 2787 (76.3) | 131 (61.5) | 0.49 (0.371–0.66) | <0.001 | 0.73 (0.524–1.01) | 0.059 | 0.63 (0.426–0.95) | 0.025 |
| 46–55 y | 3757 (73.4) | 3482 (74.5) | 275 (61.6) | 0.55 (0.448–0.67) | <0.001 | 0.74 (0.583–0.94) | 0.013 | 0.70 (0.527–0.94) | 0.018 |
| 56–65 y | 2504 (66) | 2153 (68.2) | 351 (55.3) | 0.58 (0.486–0.69) | <0.001 | 0.72 (0.584–0.88) | 0.002 | 0.70 (0.546–0.91) | 0.007 |
| 66–75 y | 1118 (57.5) | 850 (58.4) | 268 (55) | 0.87 (0.708–1.07) | 0.190 | 0.84 (0.683–1.05) | 0.128 | 0.74 (0.544–0.99) | 0.047 |
| >75 y | 388 (47.1) | 274 (48) | 114 (45) | 0.89 (0.658–1.19) | 0.426 | 0.70 (0.494–0.99) | 0.044 | 0.81 (0.512–1.29) | 0.378 |

| In-hospital mortality | | | | | | | | | |
| 18–45 y | 78 (2) | 70 (1.9) | 8 (3.7) | 2.00 (0.949–4.21) | 0.069 | 1.64 (0.642–4.19) | 0.301 | 1.21 (0.402–3.65) | 0.732 |
| 46–55 y | 194 (3.8) | 157 (3.3) | 37 (8.3) | 2.60 (1.793–3.77) | <0.001 | 2.23 (1.444–3.61) | <0.001 | 2.12 (1.261–3.56) | 0.005 |
| 56–65 y | 254 (6.7) | 177 (5.6) | 77 (12.1) | 2.32 (1.751–3.08) | <0.001 | 1.89 (1.346–2.64) | <0.001 | 1.77 (1.211–2.60) | 0.003 |
| 66–75 y | 221 (11.4) | 142 (9.7) | 79 (16.2) | 1.79 (1.331–2.41) | <0.001 | 1.60 (1.141–2.24) | 0.006 | 1.36 (0.912–2.03) | 0.131 |
| >75 y | 136 (16.5) | 85 (14.9) | 51 (20.1) | 1.44 (0.979–2.11) | 0.064 | 1.53 (0.983–2.37) | 0.060 | 1.69 (1.015–2.82) | 0.044 |

Reference group was men. P≤0.001 was considered to be statistically significant. CAGB indicates coronary artery bypass grafting; ED, emergency-department; PCI, percutaneous coronary intervention; OR, odds ratio; STEMI, ST-segment–elevation myocardial infarction.

*Adjusted for age,ethnicity, body mass index, diabetes mellitus, hypertension, smoking, history of myocardial infarction/angina, history of PCI, history of CABG, and history of stroke.

**Adjusted for age, ethnicity, body mass index, diabetes mellitus, hypertension, smoking, history of myocardial infarction/angina, history of PCI, history of CABG, history of stroke, in-hospital revascularization, and symptoms-to-ED time.

DOI: 10.1161/JAHA.119.013880
acute reperfusion therapies (thrombolytic therapies or primary PCI). Although we will not be able to explain the underlying cause, there is a need to focus on quality measures that can prevent delay in younger women in the Arabian Gulf region because a shorter time to reperfusion improves mortality. This could include the implementation of timely ECGs in emergency medical services, STEMI field activation, and direct transport of the patient to catheterization facilities to improve outcomes and to eliminate sex biases. However, we previously showed that only 5% of STEMI patients in Gulf RACE-3 (Gulf Registry of Acute Coronary Events) and 25% of the patients with ACS in Gulf RACE-1 and Gulf RACE-2 used emergency medical services in our region.26,51 In this regard, efforts should be made to improve public awareness about heart disease, particularly among younger women; to educate patients with at least 1 traditional cardiac risk factor following STEMI to utilize emergency medical services; and to regionalize care, which could reduce field delays. Further interventions are needed to encourage men and women with STEMI to seek care promptly; proactive measures should target high-risk groups (younger women) to improve care and survival of women.

Women were generally less frequently prescribed guideline-recommended pharmacotherapies than men during the acute phase and at time of discharge, which is in line with other publications.52–55 Women derive the same treatment benefit as men from aspirin, clopidogrel, beta-blockers, angiotensin-converting enzyme inhibitors and angiotensin receptor blockers, aldosterone antagonists, anticoagulants, and statins. Our results showed that women with STEMI were underprescribed beta-blockers and statins at discharge. The benefits of beta-blockers and statin therapy after STEMI were similar in both women and men (relative risk for major coronary events: 0.81 [95% CI, 0.74–0.89] and 0.82 [95% CI, 0.78–0.85], respectively).56,57 Further studies are needed to explore the contribution of the underutilization of guideline-recommended pharmacologic therapies in women to mortality outcomes.

Our study has the major strength of a large sample size with statistical power that enabled us to compare women and men among the different age subgroups by pooling data from 7 ACS registries over a 12-year time period. However, as with any other observational study, our study has inherent limitations, such as the possibility of residual measured or unmeasured confounding variables. The data presented in this analysis were from patients who enrolled voluntarily in the registries at participating study hospitals across the Arabian Gulf region from 2005 to 2017; therefore, we cannot generalize our findings to all patients with STEMI, and the patients may appear in >1 registry. The reasons for delay in presentations, the severity of comorbidities, and receipt or not of revascularization could not be ascertained. Last, the 1-year follow-up data were available in only 4 of the 7 pooled ACS registries.

**Conclusions**

Women were less likely to receive guideline-recommended pharmacotherapies at hospital discharge than men across all age groups. Younger women (aged ≤65 years) had higher crude and adjusted in-hospital and 1-year mortality rates than younger men. Consequently, interventions that reduce variations in practice at the community, institutional, and regional levels are needed to improve outcomes in women with STEMI, particularly those aged <65 years. Public awareness campaigns targeting women, such as the American Heart Association’s Go Red campaign, are urgently needed in the Arabian Gulf region.

**Acknowledgments**

The authors acknowledge the Gulf Heart Association, the Saudi Heart Association, the College of Medicine Research Center at King Khalid University Hospital, and the King Saud University, Riyadh, Saudi Arabia.

**Sources of Funding**

The research was funded by the Deanship of Scientific Research at King Saud University, Riyadh, Saudi Arabia (research group No. RG-1436-013). This research is also
supported by Gulf Heart Association and Saudi Heart Association.

Disclosures
None.

References
1. Vedanthan R, Seligman B, Fuster V. Global perspective on acute coronary syndrome: a burden on the young and poor. Circulation. 2014;114:1959–1975.

5. Hambraeus K, Tydén P, Lindahl B. Time trends and gender differences in prevention guideline adherence and outcome after myocardial infarction: data from the SWEDHEART registry. Eur J Prev Cardiol. 2016;23:340–348.

7. Dey S, Flather MD, Devlin G, Brieger D, Gur

8. Blomkalns AL, Chen AY, Hochman JS, Peterson ED, Trynosky K, Diercks DB, Brogan GX, Boden WE, Roe MT, Ohman EM, Gibler WB. Gender disparities in the diagnosis and treatment of non-ST-elevation myocardial infarction: results from the VIRGO study. J Am Coll Cardiol. 2013;64:9–13.

16. Piackova E, Jäger B, Farhan S, Christ G, Schreiber W, Weidinger F, Stefenelli T, Delle-Karth G, Kaini M, Maier G, Huber K. Gender differences in in-hospital mortality in the Vienna STEMI registry. Int J Cardiol. 2017;244:303–308.

17. Gupta A, Barabees JA, Strait K, Bueno H, Porta-Sánchez A, Acosta-Vélez JG, Lidón RM, Spatz E, Geda M, Dreyer RP, Lorenze N. Sex differences in timeliness of reperfusion in young patients with ST-segment elevation myocardial infarction by initial electrocardiographic characteristics. J Am Heart Assoc. 2018;7:e007021.

18. Canto JG, Rogers RJ, Goldberg RJ, Peterson ED, Wenger NK, Vaccarino V, Kiefe CI, Frederick PD, Sopko G, Zheng Z. Association of age and sex with myocardial infarction symptom presentation and in-hospital mortality. JAMA. 2012;307:813–822.

19. Kaul P, Armstrong PW, Sookram S, Leung BK, Brass N, Welsh RC. Temporal trends in patient and treatment delay among men and women presenting with ST-elevation myocardial infarction. Am Heart J. 2011;161:91–97.

20. Benamer H, Tafflet M, Bataille S, Escolano S, Livarek B, Fourchard V, Causmin C, Teiger E, Garot P, Lambert Y, Jouven X. Female gender is an independent predictor of in-hospital mortality after STEMI in the era of primary PCI: insights from the greater Paris area PCI registry. Eurointervention. 2011;6:1073–1079.

21. El-Menyar A, Zubaid M, Sulaiman K, Almahmed W, Singh R, Alsheikh-Ali AA, Suwaidi J: Gulf Registry of Acute Coronary Events (Gulf Race) Investigators. Atypical presentation of acute coronary syndrome: a significant independent predictor of in-hospital mortality. J Cardiovasc Risk. 2011;17:165–171.

22. Khesroh AA, Al-Roumi F, Al-Zakwani I, Attur S, Rashied M, Zubaid M. Gender differences among patients with acute coronary syndrome in the Middle East. Heart Views. 2017;18:71–74.

23. El-Menyar A, Rashied M, Rashied W, Almahmed W, Al-Lawati J, Sulaiman K, Al-Motareb A, Amin H, Singh R, Al Suwaidi J. Comparison of men and women with acute coronary syndrome in six Middle Eastern countries. Am J Cardiol. 2009;104:1018–1022.

24. Al HabibKF, Hersi A, AlFaleh H, AlNemer K, AlSaif S, Aronow WS, Ahn C, Auffret V, ElKhoury C, Le

25. Khera S, Kolte D, Gupta T, Subramanian KS, Khanna N, Aronow WS, Abn C, Timmermans RJ, Cooper HA, Fonarow GC, Frishman WH. Temporal trends and 5-year outcome of young patients (≤55 years) with acute coronary syndrome. Am J Med. 2017;130:1324.e15–1324.e22.

26. AlHabib KF, Sulaiman K, Al Suwaidi J, Almahmed W, Alsheikh-Ali AA, Amin H, Al Jarallah M, AlFaleh H, Pandurangana P, Hersi A, Kashour T. Patient and system-related delays of emergency medical services use in acute ST-Elevation myocardial infarction practices and outcomes in Arabian Gulf countries (Gulf COAST registry). Heart Views. 2017;18:41–43.

27. Alhabib KF, Kinsara AJ, Alghamdi S, Al-Murayeh M, Hussein GA, AlSaif S, Khalaf H, AlFaleh H, Hersi A, Kashour T, Salah A. The first French Meta-registry, 2005–2012 patient-level pooled analysis. JA m.

28. Al Faleh H, Al Suwaidi J, Hersi A, Al Faleh H. Gender differences in acute myocardial infarction symptom presentation and in-hospital mortality. Int J Cardiol. 2012;167:1313–1317.

29. Otera PT, Kushner FG, Aschheim DD, Casey DE, Chung MK, De Lemos JA, Futterer SM, Fang JC, Fesmire FM, Franklin BA, Granger CB, Krumholz HM, Linderbaum JA, Morrow DA, Newby LK, Ornato JP, Ou N, Radford MJ, Tamis-
Holland JE, Tommaso JE, Tracy CM, Woo YJ, Zhao XC. CF/AHA Task Force. 2013 ACCF/AHA guideline for the management of ST-elevation myocardial infarction: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. Circulation. 2013;127:529–555.

32. Authors/Task Force members, Windecker S, Kolh P, Alfons F, Collet JP, Cremer J, Falk V, Filippatos G, Hamm C, Head SI, Juni P. 2014 ESC/EACTS guidelines on myocardial revascularization: the Task Force on Myocardial Revascularization of the European Society of Cardiology (ESC) and the European Association for Cardio-Thoracic Surgery (EACTS) developed with the special contribution of the European Association of Percutaneous Cardiovascular Interventions (EAPCI). Eur Heart J. 2014;35:2541–2619.

33. Authors/Task Force Members, Steg PG, James SK, Atar D, Badano LP, Barth.

35. Authors/Task Force Members, Van de Werf F, Bax J, Betriu A, Claeyns M, Danchin N. Reperfusion therapy for ST elevation acute myocardial infarction in Europe: description of the current situation in 30 countries. Eur Heart J. 2009;31:943–957.

36. Gupta T, Kolte D, Khera S, Agarwal N, Villablanca PA, Goel K, Patel K, Aronow WS.

37. Mamdani M, Sykora K, Li P, Normand SL, Streiner DL, Austin PC, Rochon PA, Anderson GM. Reader’s guide to critical appraisal of cohort studies: 2. Assessing potential for confounding. BMJ. 2005;330:960–962.

38. Champney KP, Frederick PD, Bueno H, Parashar S, Foody J, Merz CN, Canto JG, Lichtman JH, Vaccarino V. The joint contribution of sex, age and type of ischaemic heart disease in women. Nat Rev Cardiol. 2014;11:900–919.

39. Valero-Masa MJ, Velázquez-Rodríguez J, Diez-Delhoyo F, Devesa C, Juárez M, Sousa-Casasnovas I, Angulo-Llanos R, Fernández-Avilés F, Martínez-Sellés M. Sex differences in acute myocardial infarction: is it only the age? Int J Cardiol. 2017;231:36–41.

40. Barthélémy O, Degrell P, Berman E, Kneissl M, Petroni T, Silvain J, Payot L, Choussat R, Collet JP, Helft G, Montalescot G. Sex-related differences after contemporary primary percutaneous coronary intervention for ST-segment elevation myocardial infarction. Arch Cardiovasc Dis. 2015;108:428–436.

41. Vaccarino V, Badimon L, Corti R, De Wit C, Dorobantu M, Manfrini O, Koller A, Pries A, Cereno E, Bugiardini R. Presentation, management, and outcomes of ischaemic heart disease in women. Nat Rev Cardio. 2013;10:508.

42. Radovanovic D, Erne P, Urban P, Bertel O, Rickli H, Gaspoz JM. Gender differences in management and outcomes in patients with acute coronary syndromes: results on 20 290 patients from the AMIS Plus registry. Heart. 2007;93:1369–1375.

43. Bavishi C, Bangalore S, Patel D, Chatterjee S, Trivedi V, Tamis-Holland JE. Short and long-term mortality in women and men undergoing primary angioplasty: a comprehensive meta-analysis. Int J Cardiol. 2015;198:123–130.

44. Redfors B, Angerås Ø, Rämunddal T, Petursson P, Haraldsson I, Dworeck C, Odenstedt J, Ioannes D, Rawn-Fischer A, Wellin P, Sjöland H. Trends in gender differences in cardiac care and outcome after acute myocardial infarction in western Sweden: a report from the Swedish web system for enhancement of evidence based care in heart disease evaluated according to recommended therapies (SWEDEHEART). J Am Heart Assoc. 2015;4:e001995. DOI: 10.1161/JAHA.115.001995.

45. Izadnegahdar M, Singer J, Lee MK, Gao M, Thompson CR, Kopec J, Humphries KH. Do younger women fare worse? Sex differences in acute myocardial infarction hospitalization and early mortality rates over ten years. J Women Health. 2014;23:10–17.

46. Jinel H, Fonarow GC, Cannon CP, Hernandez AF, Palacios IF, Maree OA, Wells Q, Borkutz B, LaBreche KA, Liang L, Hong Y. Sex differences in medical care and early death after acute myocardial infarction. Circulation. 2008;118:2803–2810.

47. Bugiardini R, Ricci B, Cenko E, Vasičević Z, Kedey S, Davidovic G, Zdravkovic M, Mičić D, Dolic M, Manfrini O, Koller A. Delayed care and mortality among women and men with myocardial infarction. J Am Heart Assoc. 2017;6: e005968. DOI: 10.1161/JAHA.117.005968.

48. Shaw LJ, Merz CN, Pepine CJ, Reis SE, Kelsey SF, Olson M, Johnson BD, Mankad S, Sharafi BL, Rogers WJ. Insights from the NHLBI-sponsored Women’s Ischemia Syndrome Evaluation (WISE) Study: Part I: gender differences in traditional and novel risk factors, symptom evaluation, and gender-optimized diagnostic strategies. J Am Coll Cardiol. 2006;47:S4–S20.

49. Johnston N, Bornefalk-Hermansson A, Schenck-Gustafsson K, Held C, Goodman SG, Yan AT, Bierman AS. Do clinical factors explain persistent sex disparities in the use of acute reperfusion therapy in STEMI in Sweden and Canada? Eur Heart J. Acute Cardiovasc Care. 2013;2:359–358.

50. Dreyer RP, Beltrame JF, Tavella R, Air T, Hoffmann B, Patti PK, Di Fiore D, Arstall M, Zeltz C. Evaluation of gender differences in door-to-balloon time in ST-elevation myocardial infarction. Heart Lung Circ. 2013;22:861–869.

51. Al-Habib KF, Alfalah H, Hersi A, Kashour T, Alsheikh-Ali AA, Suwaidi JA, Sulaiman K, Sait SA, Almahmeed W, Aasaad N, Amin H. Use of emergency medical services in the second gulf registry of acute coronary events. Angiology. 2014;65:703–709.

52. Nauta ST, Deckers JW, van Domburg RT, Akkerhuis KM. Gender-related trends in mortality in hospitalized men and women after myocardial infarction between 1985 and 2008: equal benefit for women and men. Circulation. 2012;126:2184–2189.

53. Wei J, Mehta PK, Grey E, Garberich RF, Hauser R, Merz CN, Henry TD. Sex-based differences in quality of care and outcomes in a health system using a standardized STEMI protocol. Am Heart J. 2017;191:30–36.

54. Wenger NK. Women and coronary heart disease: a century after Herrick: understood, underdiagnosed, and undertreated. Circulation. 2012;126:604–611.

55. Radovanovic D, Seifert B, Roffi M, Urban P, Rickli H, Pedrazzini G, Erne P. Gender differences in the decrease of in-hospital mortality in patients with acute myocardial infarction during the last 20 years in Switzerland. Open Heart. 2017;4:e000689.

56. Bangalore S, Makani H, Radford M, Thakur K, Toklu B, Katz SD, DiNicolantonio JJ, Devereaux PJ, Alexander KP, Wettleslev J, Messerli FH. Clinical outcomes with β-blockers for myocardial infarction: a meta-analysis of randomized trials. Am J Med. 2014;127:939–953.

57. Gutierrez J, Ramirez G, Rundek T, Sacco RL. Statin therapy in the prevention of recurrent cardiovascular events: a sex-based meta-analysis. Arch Intern Med. 2012;172:909–919.